New strategy aims to stop Cancer's return after transplant
NCT ID NCT03652441
Summary
This study tested whether giving a drug called brentuximab vedotin for up to one year after a stem cell transplant could help prevent Hodgkin lymphoma from coming back. The treatment was given to 14 adults whose cancer had returned or hadn't responded to previous treatments. Researchers wanted to see if this 'consolidation therapy' could improve disease control and survival after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Conditions
Explore the condition pages connected to this study.